Low-dose nivolumab plus chemo for early lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC) at stage IB, II, or IIIA that can be removed with surgery.
- Your tumor must not have certain genetic changes: no EGFR mutation, and no ALK or ROS1 proteins.
- Your doctor has measured the PD-L1 protein level in your tumor.
- You must be in good general health (able to do daily activities without help) and have adequate organ function (kidneys, liver, blood counts).
- You cannot have received any prior cancer treatment for NSCLC, including chemotherapy, immunotherapy, or targeted therapy.
- You cannot be pregnant or breastfeeding, and you must agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
This study looks at how well the immunotherapy drug nivolumab (Opdivo) works when given with standard chemotherapy before surgery for people with a certain type of lung cancer that has not spread. It may help shrink the tumor before surgery.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
Hear when a new Lung Cancer, Nonsmall Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.